The biological distinction between GBM subtypes impacts prognosis and therapy, with IDH-mutant (secondary) GBM showing better outcomes and greater chemosensitivity than IDH-wildtype (primary) GBM [24]. The gene discussed is IDH1; the disease is glioblastoma.